Benzinga | Aug 18, 2020 04:12PM EDT

Timber Pharmaceuticals Says Phase 2b Clinical Trials for Each of the Company's Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned

Phase 2b Clinical Trials for Each of the Company's Lead Assets in Orphan Dermatologic Diseases are Progressing as Planned

WOODCLIFF LAKE, NJ, Aug. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter of 2020, ended June 30, 2020.

"Since Timber became a public company in mid-May, we have continued to execute on our strategic plan to develop and commercialize treatments for orphan and rare dermatologic diseases. Orphan and rare dermatology remains a very attractive market for Timber, as we believe the seven years of U.S. market exclusivity provided for the drugs in our strategic pipeline will enable them to reach considerable value in the marketplace," said John Koconis, Chief Executive Officer of Timber.

"During the second quarter we announced that all 11 sites in the CONTROL trial are open for TMB-001, and a significant portion have also opened for TMB-002, enabling us to expand the enrollment of patients in each of the Phase 2b clinical trials. We expect to complete the enrollment of patients in both the TMB-001 and TMB-002 studies during the early months of 2021. We are also working to advance the strategic options for the two assets we obtained in the merger with BioPharmX. We believe these efforts are strengthened by the notice we recently received from the European Patent Office (EPO) that it intends to grant a patent for the Company's topical composition of pharmaceutical tetracycline (including minocycline) for dermatological use. Patents covering the BPX-01 and BPX-04 assets have previously been granted in the United States, South Africa and claims related to the patents have been allowed in Australia.

"We encountered significant one-time charges and expenses in connection with our merger and financing which are now behind us. We expect that our cash balance of nearly $14 million will fund our trials and operations through the completion of both the current TMB-001 and TMB-002 studies, which are expected to conclude in Q3 2021. With the merger-related costs now behind us, the Phase 2b clinical trials well underway, and supported by a strong balance sheet, we believe that Timber is well positioned to achieve its goals," concluded Mr. Koconis.

For Timber's complete financial results for the period ended June 30, 2020, see the Company's quarterly Form 10-Q filed with the Securities and Exchange Commission on August 18, 2020.